Healthcare Industry News: Acute Coronary Syndrome
News Release - May 10, 2016
Medicure Announces Departure of President and Chief Operating OfficerWINNIPEG, May 9, 2016 -- (Healthcare Sales & Marketing Network) - Medicure Inc. ("Medicure") (TSXV:MPH, OTC:MCUJF), a specialty pharmaceutical company today announced that the employment agreement with President and Chief Operating Officer, Dawson Reimer, has been terminated, effective immediately. "I and the entire Board of Directors thank Dawson for his commitment and dedication throughout his years of service with Medicure. We wish him all the best in his new endeavours," said Dr. Albert Friesen, Board Chair and CEO of Medicure Inc.
Dr. Friesen, founder of Medicure, will, in addition to his current responsibilities, take on the role of President of the Company, while oversight of the operations function will be assumed by other members of the management team. "Our experienced leadership team will continue to focus on the advancement of AGGRASTAT and growth of Medicure," said Dr. Friesen.
About Medicure Inc.
Medicure is a specialty pharmaceutical company focused on the development and commercialization of therapeutics for the U.S. hospital market. The primary focus of the Company and its subsidiaries is the marketing and distribution of AGGRASTAT (tirofiban HCl) for non-ST elevation Acute Coronary Syndrome in the United States, where it is sold through the Company's U.S. subsidiary, Medicure Pharma, Inc. For more information on Medicure please visit www.medicure.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.